• Hyloris Developments SA hosted an exclusive company visit for members of VFB at its headquarters in Liège, alongside neighboring listed company Nyxoah.
• CEO Stijn Van Rompay outlined the company’s strategy and pipeline of more than 30 drug candidates, highlighting 2025 progress including six portfolio additions and eight out-licensing deals, followed by a tour of its R&D laboratories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyloris Developments SA published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.